Señales en vivo de DSRLF | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 may 2024 @ 13:35):

Stats
Volumen de hoy	100.00
Volumen promedio	3.00
Capitalización de mercado	5.82B
EPS	$0 ( 2024-05-15 )
Próxima fecha de ganancias	( $0 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	33.85
ATR14	$0 (0.00%)

DiaSorin S.p.A. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

DiaSorin S.p.A. Finanzas

Annual	2023
Ingresos:	$1.27B
Beneficio Bruto:	$738.49M (58.27 %)
EPS:	$3.16

FY	2023
Ingresos:	$1.27B
Beneficio Bruto:	$738.49M (58.27 %)
EPS:	$3.16

FY	2022
Ingresos:	$1.46B
Beneficio Bruto:	$884.57M (60.72 %)
EPS:	$4.46

Financial Reports:

No articles found.

DiaSorin S.p.A. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

DiaSorin S.p.A.

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.